SCHEMBL5049281

SCHEMBL5049281

C=CCOc1ccc(CCl)c(F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ADRA2A P08913 1/20 0.42
ADRA2B P18089 1/20 0.42
ADRA2C P18825 1/20 0.42
CA12 O43570 5/20 0.41
CA1 P00915 5/20 0.41
CA9 Q16790 5/20 0.41
HPGD P15428 3/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
MAOB P27338 2/20 0.39
ALDH1A1 P00352 2/20 0.39
AOC3 Q16853 1/20 0.39
KAT6A Q92794 1/20 0.38
AGER Q15109 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5047814 0.83 MAPT (0.46) MAPTMEN1LMNAKMT2ASMN1; SMN2
SCHEMBL27957723 0.82 MAPT (0.50) MAPTMEN1LMNAKMT2ASMN1; SMN2
SCHEMBL7109956 0.81 MEN1 (0.44) MAPTMEN1LMNAKMT2ASMN1; SMN2
SCHEMBL4516014 0.80 HPGD (0.47) MAPTMEN1LMNAKMT2ASMN1; SMN2
SCHEMBL17460040 0.77 MTNR1A (0.43) MAPTMEN1LMNAKMT2ASMN1; SMN2
SCHEMBL26335041 0.76 MAPT (0.38) MAPTMEN1LMNAKMT2ASMN1; SMN2
SCHEMBL21736861 0.76 ALDH1A1 (0.49) MAPTMEN1LMNAKMT2ASMN1; SMN2
SCHEMBL5439339 0.76 MAPT (0.45) MAPTMEN1LMNAKMT2ASMN1; SMN2
SCHEMBL26335081 0.76 MAPT (0.49) MAPTMEN1LMNAKMT2ASMN1; SMN2
SCHEMBL4740058 0.74 MAPT (0.46) MAPTMEN1LMNAKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7432291-B2 Ether derivatives HOFFMAN-LA ROCHE INC. (US) 2008-10-07 US disclosed
EP-1727815-B1 ETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2007-06-27 EP disclosed
CN-1930154-A Ether derivatives, their manufacture and use as pharmaceutical agents HOFFMANN LA ROCHE (CH) 2007-03-14 CN disclosed
US-20050209290-A1 Novel ether derivatives F. HOFFMAN-LA ROCHE AG (CH) 2005-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209290-A1 Novel ether derivatives CYP2E1, CYP11B1, CYP11B2 MAPT 4504/4885MEN1 1689/4885LMNA 791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.